Call: 0123456789 | Email: info@example.com

The U.S. debt-to-gross-domestic-product

The U.S. debt-to-gross-domestic-product


Everyone is aware of the budget deficit in the U.S. Last year, the deficit was $1.3 trillion, and we are certainly on track to at least match that deficit in 2012. The U.S. debt-to-gross-domestic-product (GDP) level is at 100% —one dollar of debt for every dollar of revenue generated—and climbing.

With this in mind, investors should think of diversifying some of their money out of U.S. dollars, and owning countries that have not printed money and the deficits of which are not as large as countries like the U.S.

Australia and Canada are two countries that have their budget houses in order. Australia’s latest debt-to-GDP is just over 26%, which means the country has $0.26 of debt for every dollar of revenue generated. Like a household, this is clearly a healthy level of debt that can be paid off, even if the economy contracts.

In Canada, the debt-to-GDP is roughly over 67%, which means the country has $0.67 of debt for every dollar of revenue generated. These are numbers that are not as low as Australia’s numbers, but clearly a more sustainable level than the U.S.

Should economic growth continue to worsen around the world, countries like Australia and Canada will be in a better position to ride out the bad times. Naturally, their currencies will strengthen as a consequence.

Also, because they are healthier countries in general, even if economic growth picks up, these countries will continue to attract investors to their currencies, because they are in much better fiscal shape than the U.S.

Not only are these currencies safer investments, but these countries are also home to some of the largest gold mining stocks in the world.

We at Penny Stock Detectives believe that the bull market in gold bullion and gold mining stocks still has a long way to run. Thus far in 2012, gold bullion has been one of the best performing asset classes in the stock market. Although the gold mining stocks have participated to a limited extent, gold mining stocks are still undervalued compared to the price of gold bullion. for more details, visit : http://smallbusinesseurope.org/internet-for-new-stock-newsletters/

Gold mining stocks are roughly pricing in a longer-term price of gold bullion between $1,300 and $1,400. This means that, if gold bullion continues to rise past $2,000, this will make gold mining stocks even more inexpensive.

Penny Stock Detectives strongly believe that, if gold bullion rises above $2,000, it will attract new investor money into gold mining stocks. When new investors look to invest in the gold sector, they can either buy gold bullion at $2,000 or the gold mining stocks that are trading at levels that reflect gold bullion at $1,300-$1,400. We think new investors will choose gold mining stocks.

With their economic houses in better shape than most countries in the world, the Australian and Canadian dollars are currencies that Penny Stock Detectives believes an investor should own. Home to some of the largest gold mining stocks in the world, investors can own these strong currencies by owning gold mining stocks, which are trading at a discount to the current price of gold bullion. Protection with great upside.

RSS Stock Market

  • Verastem Inc. (VSTM:NASDAQ) September 29, 2020
    Verastem Inc. (VSTM:NASDAQ) Verastem Inc. (VSTM:NASDAQ) has a market cap of $80M. A Biotech Watchlist veteran, Verastem is attempting to lift itself up in the wake of the significant Phase 2 COMMAND trial disappointment. New preclinical information has risen with respect to the utilization of central bond kinase (FAK) and protein tyrosine kinase-2 (PYK2) inhibitors […]
  • Tokai Pharmaceuticals’ (NASDAQ:TKAI) September 29, 2020
    Tokai Pharmaceuticals’ (NASDAQ:TKAI) The business case for Tokai Pharmaceuticals’ (NASDAQ:TKAI) lead prostate malignancy venture, galeterone, was flawed well before late 70% breakdown in the gathering’s share price. Also, the issues were more basic even than the way that the maim safe prostate growth field has been shaken up to the point of being unrecognizable by […]
  • Tonix Pharmaceuticals Holding Corp. (TNXP) September 29, 2020
    Tonix Pharmaceuticals Holding Corp. (TNXP) As of late, Tonix Pharmaceuticals Holding Corp. (TNXP) reported that it had fizzled its stage 3 trial in patients with Fibromyalgia. The stage 3 trial, known as the “Certify” trial, neglected to meet on the essential endpoint of the study. The trial was outlined in such an approach to test […]
  • Threshold Pharmaceuticals (THLD) September 29, 2020
    Threshold Pharmaceuticals (THLD) Shares of Threshold Pharmaceuticals (THLD) were spiking on substantial exchanging volume as kindred medication producer Medivation (MDVN) consented to be purchased by Pfizer (PFE) for $14 billion. A South San Francisco-based clinical stage biopharmaceutical organization concentrated on the disclosure and improvement of disease therapeutics. Around 14.41 million of the organization’s shares changed […]
  • Theravance Biopharma (NASDAQ:TBPH) September 29, 2020
    Theravance Biopharma (NASDAQ:TBPH) With no uncertainty, Theravance Biopharma (NASDAQ:TBPH) is one of the best outperformers of the previous 12 months. It has outflanked IBB by 140% and the NASDAQ by 116%. This may have driven a few financial specialists to trust the gathering won’t keep going long any longer. Before that, the stock had really […]
  • StemCells (NASDAQ:STEM) September 29, 2020
    StemCells (NASDAQ:STEM) StemCells (NASDAQ:STEM) went up 598.55% in a solitary day. StemCells surged altogether taking after its declaration of going to enter an opposite merger with an Israeli organization named Microbot Medical. Microbot Medical is a privately owned business, by converging with StemCells, it will end up being an open organization under StemCells’ available posting. […]
  • Synthetic Biologics Inc. (SYN) September 29, 2020
    Synthetic Biologics Inc. (SYN) Numerous financial specialists like to search for momentum stocks, yet this can be extremely difficult to characterize. There is incredible level headed discussion with respect to which measurements are the best to concentrate on in such manner, and which are not by any means quality pointers of future execution. Luckily, with […]
  • Synergy Pharmaceuticals (NASDAQ:SGYP) September 29, 2020
    Synergy Pharmaceuticals (NASDAQ:SGYP) Synergy Pharmaceuticals (NASDAQ:SGYP) is a little top exploration stage biotech organization recorded on the Nasdaq. With a share price around $3 and a business sector top around $600 million, SGYP will have a noteworthy impetus in IBS-Constipation in Q3 2016. In the event that this Phase 3 trial is effective, the stock […]
  • Immune Pharmaceuticals (NASDAQ:IMNP) September 29, 2020
    Immune Pharmaceuticals (NASDAQ:IMNP) Immune Pharmaceuticals (NASDAQ:IMNP) is pushing forward with a multi-pronged way to deal with battling malignancy. Over the previous year, it has essentially extended its immuno-oncology (I/O) senior initiative to drive this exertion forward. Their endeavors in I/O are going up by Miri Ben-Ami, MD, a previous senior official at Teva, Monica Luchi, […]
  • Ignyta Inc. (RXDX:NASDAQ) September 29, 2020
    Ignyta Inc. (RXDX:NASDAQ) Ignyta Inc. (RXDX:NASDAQ) has a $420M market cap. Ignyta takes a targeted approach to oncology, focusing on integrated therapies and diagnostics. This methodology derisks its clinical trials. The company has an efficient “basket design” that allows for multiple data points, a big pipeline and an aggressive business development strategy. The company is […]